[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

Oncogene volume 27, pages 5797–5807 (2008)Cite this article

Abstract

Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers. An extensive medicinal chemistry study, designed to generate more potent analogues of roscovitine, led to the identification of an optimal substitution at the N6 position (compound CR8). An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9. CR8 was 2- to 4-fold more potent than (R)-roscovitine at inhibiting these kinases. Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions. The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells. CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25–50 times higher potency compared to (R)-roscovitine. CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction (40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose)polymerase cleavage (50-fold). This improved cell death-inducing activity of CR8 over (R)-roscovitine was observed in 25 different cell lines. Altogether these results show that second-generation analogues of (R)-roscovitine can be designed with improved antitumor potential.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

Abbreviations

CDK:

cyclin-dependent kinase

CK1:

casein kinase 1

DMSO:

dimethylsulfoxide

GSK-3:

glycogen synthase kinase-3

LDH:

lactate dehydrogenase

MTS:

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

PBS:

phosphate-buffered saline

PP1α:

protein phosphatase 1α

Rb:

retinoblastoma protein

References

  • Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B et al. (2005). Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280: 31208–31219.

    Article  CAS  Google Scholar 

  • Bain J, McLauchlan H, Elliott M, Cohen P . (2003). The specificities of protein kinase inhibitors: an update. Biochem J 371: 199–204.

    Article  CAS  Google Scholar 

  • Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297–315.

    Article  CAS  Google Scholar 

  • Becker F, Murthi K, Smith C, Come J, Costa-Roldan N, Kaufmann C et al. (2004). A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem Biol 11: 211–223.

    Article  CAS  Google Scholar 

  • Behrend L, Milne DM, Stoter M, Deppert W, Campbell LE, Meek DW et al. (2000). IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene 19: 5303–5313.

    Article  CAS  Google Scholar 

  • Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C et al. (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96: 29–37.

    Article  CAS  Google Scholar 

  • Brown NR, Noble ME, Endicott JA, Johnson LN . (1999). The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol 1: 438–443.

    Article  CAS  Google Scholar 

  • Cai D, Latham Jr VM, Zhang X, Shapiro GI . (2006). Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 66: 9270–9280.

    Article  CAS  Google Scholar 

  • Chang YT, Gray NG, Rosania GR, Sutherlin DP, Kwon S, Norman TC et al. (1999). Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol 6: 361–375.

    Article  CAS  Google Scholar 

  • Collaborative Computational Project, Number 4 (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr D50: 760–763.

    Google Scholar 

  • de la Motte S, Gianella-Borradori A . (2004). Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 42: 232–239.

    Article  CAS  Google Scholar 

  • Emsley P, Cowtan K . (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D 60: 2126–2132.

    Article  Google Scholar 

  • Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329–336.

    Article  CAS  Google Scholar 

  • Fischer PM, Gianella-Borradori A . (2005). Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 14: 457–477.

    Article  CAS  Google Scholar 

  • Goga A, Yang D, Tward AD, Morgan DO, Bishop JM . (2007). Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 13: 820–827.

    Article  CAS  Google Scholar 

  • Gray N, Wodicka L, Thunnissen AM, Norman T, Kwon S, Espinoza FH et al. (1998). Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 281: 533–538.

    Article  CAS  Google Scholar 

  • Guzi T . (2004). Cyc-202 Cyclacel. Curr Opinion Investig Drugs 5: 1311–1318.

    CAS  Google Scholar 

  • Haesslein JL, Jullian N . (2002). Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. Curr Top Med Chem 2: 1037–1050.

    Article  CAS  Google Scholar 

  • Hallaert DY, Spijker R, Jak M, Derks IA, Alves NL, Wensveen FM et al. (2007). Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 14: 1958–1967.

    Article  CAS  Google Scholar 

  • Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G et al. (1997). Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity olomoucine and related compounds. J Med Chem 40: 408–412.

    Article  CAS  Google Scholar 

  • Kapasi AJ, Spector DH . (2008). Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. J Virol 82: 394–407.

    Article  CAS  Google Scholar 

  • Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Wurl PU et al. (2005). The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 28: 508–514.

    CAS  PubMed  Google Scholar 

  • Knockaert M, Greengard P, Meijer L . (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23: 417–425.

    Article  CAS  Google Scholar 

  • Kostich M, English J, Madison V, Gheyas F, Wang L, Qiu P et al. (2002). Human members of the eukaryotic protein kinase family. Genome Biol 3: Research0043.

    Article  Google Scholar 

  • Kwon YG, Lee SY, Choi Y, Greengard P, Nairn AC . (1997). Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proc Natl Acad Sci USA 94: 2168–2173.

    Article  CAS  Google Scholar 

  • Langston JW, Ballard P, Tetrud JW, Irwin I . (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.

    Article  CAS  Google Scholar 

  • Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS et al. (2000). Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J Med Chem 43: 1282–1292.

    Article  CAS  Google Scholar 

  • Malumbres M, Barbacid M . (2005). Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630–641.

    Article  CAS  Google Scholar 

  • Malumbres M, Pevarello P, Barbacid M, Bischoff JR . (2007). CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol Sci 29: 16–21.

    Article  Google Scholar 

  • Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S . (2002). The protein kinase complement of the human genome. Science 298: 1912–1934.

    Article  CAS  Google Scholar 

  • McClue SJ, Blake B, Clarke R, Cowan A, Cummings L, Fischer PM et al. (2002). In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102: 463–468.

    Article  CAS  Google Scholar 

  • McClue SJ, Stuart I . (2007). Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor Seliciclib (R-Roscovitine) in vitro and in vivo. Drug Metab Dispos 29: 561–570.

    Article  Google Scholar 

  • Meijer L, Bettayeb K, Galons H . (2006). Roscovitine (CYC202, Seliciclib). In: Smith PJ and Yue E (eds). Monographs on Enzyme Inhibitors. CDK Inhibitors and their Potential as Anti-Tumor Agents. CRC Press, Taylor & Francis: Boca Raton, Fl, vol. 2., chapter 9, pp 187–226.

    Google Scholar 

  • Meijer L, Borgne A, Mulner O, Chong JPJ, Blow JJ, Inagaki N et al. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527–536.

    Article  CAS  Google Scholar 

  • Meijer L, Raymond E . (2003). Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36: 417–425.

    Article  CAS  Google Scholar 

  • Misra RN . (2006). Clinical progress of selective cyclin-dependent kinase (CDK) inhibitors. Drugs of the Future 31: 43–52.

    Article  CAS  Google Scholar 

  • Murshudov GN, Vagin AA, Dodson EJ . (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D 53: 240–255.

    Article  CAS  Google Scholar 

  • Niedner RH, Buzko OV, Hatse NM, Taylor A, Gribskov M, Taylors SS . (2006). Protein kinase resource: an integrated environment for phosphorylation research. Proteins 63: 78–86.

    Article  CAS  Google Scholar 

  • Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM et al. (2005). Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 4: 125–139.

    Article  CAS  Google Scholar 

  • Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard M-L et al. (2008). Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases (CDKs) and casein kinase 1 (CK1). J Med Chem (in press).

  • Payton M, Chung G, Yakowec P, Wong A, Powers D, Xiong L et al. (2006). Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 66: 4299–4308.

    Article  CAS  Google Scholar 

  • Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE et al. (2005). In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11: 4875–4887.

    Article  CAS  Google Scholar 

  • Reinhardt J, Ferandin Y, Meijer L . (2007). Purification CK1 by affinity chromatography on immobilised axin. Protein Expr & Purif 54: 101–109.

    Article  CAS  Google Scholar 

  • Ribas J, Bettayeb K, Ferandin Y, Garrofé-Ochoa X, Knockaert M, Totzke F et al. (2006a). 7-bromoindirubin-3′-oxime induces caspase-independent cell death. Oncogene 25: 6304–6318.

    Article  CAS  Google Scholar 

  • Ribas J, Boix J . (2004). Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp Cell Res 295: 9–24.

    Article  CAS  Google Scholar 

  • Ribas J, Boix J, Meijer L . (2006b). (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res 312: 2394–2400.

    Article  CAS  Google Scholar 

  • Shapiro GI . (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770–1783.

    Article  CAS  Google Scholar 

  • Smith PJ, Yue E (Editors) (2006). CDK Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents. Monographs on Enzyme Inhibitors. CRC Press, Taylor & Francis: Boca Raton, Fl, vol. 2., 448 pp.

    Book  Google Scholar 

  • Tang L, Li MH, Cao P, Wang F, Chang WR, Bach S et al. (2005). Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 280: 31220–31229.

    Article  CAS  Google Scholar 

  • Vandromme L, Piguel S, Lozach O, Meijer L, Legraverend M, Grierson DS . (2006). Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors. Bioorg Med Chem Lett 16: 3144–3146.

    Article  CAS  Google Scholar 

  • Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Siden A et al. (2005). Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 25: 91–103.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to J Boix, C Guillouzo and J Mester for cell lines, G Ponzio for the human foreskin primary fibroblasts, Dr Michael Kubbutat (ProQinase, Freiburg, Germany) and Sir Philip Cohen (Dundee, UK) for the selectivity panel assays and to the beamline scientists at the ESRF (ID14-EH-2 and ID14-EH-1) for providing excellent facilities for crystal data collection. This research was supported by grants from the EEC (FP6-2002-Life Sciences and Health, PRO-KINASE Research Project) (LM, JE), the ‘Cancéropole Grand-Ouest’ grant (LM), the ‘Institut National du Cancer’ (INCa ‘Cancer Détection d’innovations 2006′) (LM), the ‘Association France-Alzheimer Finistère’ (LM) and the ‘Ligue Nationale contre le Cancer (Comité du Finistère)’ (LM). KB was supported by a fellowship from the ‘Ministère de la Recherche’ and from the ‘Association pour la Recherche sur le Cancer’. NO benefited from a PhD fellowship from the ‘Institut National du Cancer’. The structures of pCDK2/cyclin A/(R)-roscovitine, and pCDK2/cyclin A/(R)-CR8 have been deposited in the PDB with accession number codes 3DDQ and 3DDP, respectively.

Author information

Authors and Affiliations

  1. CNRS, Cell Cycle Group, Station Biologique, Bretagne, France

    K Bettayeb, Y Ferandin & L Meijer

  2. Laboratoire de Chimie Organique 2, INSERM U 648, Université Paris—Descartes, Paris cedex, France

    N Oumata & H Galons

  3. Department of Biochemistry, Laboratory of Molecular Biophysics, University of Oxford, Oxford, UK

    A Echalier & J A Endicott

Authors
  1. K Bettayeb
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. N Oumata
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. A Echalier
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Y Ferandin
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. J A Endicott
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. H Galons
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. L Meijer
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence to H Galons or L Meijer.

Additional information

Supplementary information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bettayeb, K., Oumata, N., Echalier, A. et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 27, 5797–5807 (2008). https://doi.org/10.1038/onc.2008.191

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2008.191

Keywords

This article is cited by

Search

Advanced search

Quick links